AU2001273405A1 - Down syndrome critical region 1-like 1 proteins - Google Patents

Down syndrome critical region 1-like 1 proteins

Info

Publication number
AU2001273405A1
AU2001273405A1 AU2001273405A AU7340501A AU2001273405A1 AU 2001273405 A1 AU2001273405 A1 AU 2001273405A1 AU 2001273405 A AU2001273405 A AU 2001273405A AU 7340501 A AU7340501 A AU 7340501A AU 2001273405 A1 AU2001273405 A1 AU 2001273405A1
Authority
AU
Australia
Prior art keywords
proteins
down syndrome
critical region
syndrome critical
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273405A
Inventor
Carla M. Edwards
Jeanne F Loring
David G. Streeter
Debora W. Tingley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Publication of AU2001273405A1 publication Critical patent/AU2001273405A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001273405A 2000-07-11 2001-07-11 Down syndrome critical region 1-like 1 proteins Abandoned AU2001273405A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/614,474 2000-07-11
US09/614,474 US6524819B1 (en) 2000-07-11 2000-07-11 Down syndrome critical region 1-like proteins
PCT/US2001/021982 WO2002004513A2 (en) 2000-07-11 2001-07-11 Down syndrome critical region 1-like 1 proteins

Publications (1)

Publication Number Publication Date
AU2001273405A1 true AU2001273405A1 (en) 2002-01-21

Family

ID=24461401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273405A Abandoned AU2001273405A1 (en) 2000-07-11 2001-07-11 Down syndrome critical region 1-like 1 proteins

Country Status (6)

Country Link
US (2) US6524819B1 (en)
EP (1) EP1356039A2 (en)
JP (1) JP2004516815A (en)
AU (1) AU2001273405A1 (en)
CA (1) CA2415127A1 (en)
WO (1) WO2002004513A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006619A2 (en) * 2001-07-13 2003-01-23 Clf Medical Technology Acceleration Program, Inc Calcineurin modulators
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
AT500321B1 (en) * 2003-12-30 2006-02-15 Red Bull Gmbh Early, prenatal diagnosis of Down syndrome, comprises detecting abnormal levels of specific proteins in fetal cells from amniotic fluid or blood, or in brain tissue
WO2005082412A1 (en) * 2004-02-26 2005-09-09 Perseus Proteomics Inc. Drug for treating and preventing cancer
CN101432302A (en) 2005-11-30 2009-05-13 艾博特公司 Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibod
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CN102482672B (en) * 2009-06-26 2016-11-09 库尔纳公司 By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723290A (en) * 1994-11-03 1998-03-03 Trustees Of The University Of Pennsylvania Methods for profiling mRNA expression in neurites
ES2154506B1 (en) * 1995-06-07 2001-11-16 Estivill Palleja Xavier CHARACTERIZATION PROCEDURE FOR A NEW MOLECULAL CLONING TECHNIQUE (PCR ALU-SPLICE) OF A GENETIC SEQUENCE OF THE HUMAN CHROMOSOME 21 AND NEW DSCRI GENETIC SEQUENCE OF THE CRITICAL SYNDROME DEDOWN OF SUCH CHROMOSOMA, CHARACTERIZED ACCORDING TO THE MACHINE.
WO2001004305A2 (en) * 1999-07-07 2001-01-18 Incyte Genomics, Inc. Human proteins involved in detoxification
AU2001264559A1 (en) * 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US7629308B2 (en) * 2000-07-07 2009-12-08 Board Of Regents, The University Of Texas System Methods relating to muscle selective calcineurin interacting protein (MCIP)

Also Published As

Publication number Publication date
US20030186333A1 (en) 2003-10-02
JP2004516815A (en) 2004-06-10
EP1356039A2 (en) 2003-10-29
CA2415127A1 (en) 2002-01-17
US6524819B1 (en) 2003-02-25
WO2002004513A3 (en) 2003-04-24
WO2002004513A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
AU2001291200A1 (en) Micro-laser
AU2001254621A1 (en) Critical illness neuropathy
AU1951201A (en) Peptide antigens
ZA995201B (en) Stabilized protein compositions.
AU6045900A (en) Interaction-activated proteins
AU2616199A (en) Novel bicyclene-substituted oxazolidinones
AU2001273405A1 (en) Down syndrome critical region 1-like 1 proteins
GB0003079D0 (en) Novel protein
AU2001259450A1 (en) Cytoskeleton-associated proteins
AU3473800A (en) Conotoxin peptides
AU2002220924A1 (en) Antibodies, peptides, analogs and uses thereof
AU2001244863A1 (en) Apoptin-associating protein
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2232399A (en) Recombinant ctb-based vaccines
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2002500A (en) Novel protein
AU7304600A (en) Novel protein
AU2001278777A1 (en) Irap-binding protein
AU2002224056A1 (en) Novel polypeptide
AU2001241044A1 (en) Mitf-associated proteins
AU6444600A (en) New protein
AU2659801A (en) Shc associated protein 140 (sap-140)
AU2091800A (en) Spermatogenesis protein
AU2001294911A1 (en) Carbohydrate-associated proteins
AU2001277614A1 (en) Novel proteins